Thanks Bear. Our A2-73 reality may be getting clearer to us but my guess is most biotech investors would scratch their head and wonder what we are doing? NO big FDA/self inflicted overhead? Impossible.
I have worked with a team to develop and apply AI driven business planning/strategic-product technology "What If" models in a previous life. Tools worked exactly as predicted and we kept growing, we added to our base portfolio/capability virtually every day. The humans in the room did not always like the responses given to 1000's of "what if" linked scenarios at first but they eventually figured out how to use and grow the technology as a complete success. Humans expected different solutions than what the system produced. Getting the right people to input their ideas/questions and thoughts was ultimately more difficult than building/running the many links to the inference engine.
One must be very precise on what is asked, which escalates quickly to getting/applying more facts. The array of knowing what we do not know can grow very quickly in such a learning process. A key will be deciding when enough, is enough.
The AVXL approach is based on addressing the CNS/AD root cause and not the symptom as has already been done for AD, as example. In fact all past AD trials and $$$billions spent by the best and the brightest have only produced evidence on what the root cause is NOT. Knowing what NOT TO DO is also critical of course But, it took them 30+ years or so to get there. Which I took as evidence they were not learning. You would think that after say 10 years and 95%+ failures some one would have asked why keep on this path? That will NOT HAPPEN with AI b/c the tool will give red flags up front and should get everyone to stop and rethink their path. We'll see. In any case this path and tool will facilitate the learning process big time.
When the thought occurred to apply the same tools and problem solving methods being used by the cancer treatment teams to CNS diseases a whole new universe was opened up. Now that Fireman's troops are on the job, new appropriate methods will be applied. They will emphasize knowledge/risk based thinking processes after/while the links are established with WW labs/clinics/academia/every petri dish and lab rat on the planet. The incentives to cure the curse of CNS will be WW before we know it, IMO.
Our Rett first client(Pts) are well chosen IMO. A rare CNS disease where patients should present rapid and convincing evidence of A2-73 efficacy (we all pray). This whole thing cannot start soon enough. Lets all hope for a financially and spiritually rewarding process outcome.
AI
